Title: Infliximab for Patients with Moderate to Severely Active Ulcerative Colitis: An Updated
Meta-Analysis of Randomized Controlled Trials
Version: 3 Date: 27 May 2025
Reviewer's report:
Reviewers' comments were addressed, and I have no further comments.
Please make small change in the abstract results part: "significantly" needs to be changed to
"significant" followed by short long-term and other results, otherwise it is out of context or
missing extra word to put the presented data in the right context.
This is a well-conducted review and meta-analysis, and an important publication.
Title: Infliximab for Patients with Moderate to Severely Active Ulcerative Colitis: An Updated
Meta-Analysis of Randomized Controlled Trials
Version: 3 Date: 27 May 2025
Reviewer's report:
Reviewers' comments were addressed, and I have no further comments.
Please make small change in the abstract results part: "significantly" needs to be changed to
"significant" followed by short long-term and other results, otherwise it is out of context or
missing extra word to put the presented data in the right context.
This is a well-conducted review and meta-analysis, and an important publication.
Please review this paper.
user
Title: Infliximab for Patients with Moderate to Severely Active Ulcerative Colitis: An Updated
Meta-Analysis of Randomized Controlled Trials
Version: 3 Date: 27 May 2025
Reviewer's report:
Reviewers' comments were addressed, and I have no further comments.
Please make small change in the abstract results part: "significantly" needs to be changed to
"significant" followed by short long-term and other results, otherwise it is out of context or
missing extra word to put the presented data in the right context.
This is a well-conducted review and meta-analysis, and an important publication.
assistant